App-Quantinova.ai

Evaluation of exosomal miRNAs from plasma as potential biomarkers for non-small-cell lung cancer.

Congying Xie - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Comparison of noninvasive hypoxia imaging with 18F-fluoroerythronitroimidazole and 18F-fluoromisonidazole PET/CT in lung cancer: A pilot clinical study.

Yuchun Wei - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Impact of age on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.

Lu Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Phase I study of icotinib combined with whole brain radiotherapy for EGFR-mutated non-small cell lung cancer patients with brain metastases: neurocognitive and quality-of-life analysis.

You Lu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Icotinib

Impact of platinum/pemetrexed versus other platinum-based regimens on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.

Xiaoyu Zhai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

Pemetrexed

Is there an optimal time to initiate adjuvant chemotherapy in order to predict the benefit of survival in NSCLC?

Xiaoyu Zhai - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

PD-L1 expression and its significance in Chinese patients with non-small cell lung cancer.

Susmita Sharma - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Neoadjuvant gefitinib for stage II-IIIA NSCLC with activating EGFR mutation (NCT01833572): an open-label, single-arm, phase II study.

Ranxia Gong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

gefitinib

A novel protein-coding and long non-coding RNA gene signature to predict prognosis of non-small cell lung cancer patients.

Mantang Qiu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Correlations between the EGFR mutation status and clinicopathological features of surgically resected non-small cell lung cancer.

Ying Jin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Whole exome sequencing analysis of the neoadjuvant bevacizumab plus pemetrexed and carboplatin for unresectable stage III lung adenocarcinoma: Results of the phase II GASTO 1001 trial.

Si-Yu Wang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Bevacizumab

Predictive value of the early response in locally advanced nonsmall cell lung cancer treated with concurrent chemoradiotherapy by 18F-alfatide RGD PET/CT.

Song Gao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Peripheral blood-based genetic signatures for early diagnosis of micro-nodular lung cancer.

Baohui Han - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

N/A

Pulmonary Sarcomatoid Carcinoma with ALK rearrangement: Frequency, Clinical-Pathological Characteristics, and Response to ALK inhibitor.

Xinru Chen - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pulmonary sarcomatoid carcinoma

Crizotinib

Impact of gender difference on adjuvant chemotherapy after radical resection in patients with non-small cell lung cancer.

Lu Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Lymph node drainage patterns in resectable non-small cell lung cancer and its clinical significance.

Gang Lin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Non Small Cell Lung cancer

N/A

Genome-wide screen of DNA methylation study in stage IIIa (N2) EGFR 19 deletion adenocarcinoma with erlotinib treatment.

Xiaomin Niu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Lung Cancer

Erlotinib hydrochloride

Stereotactic comparison study of 18F-Alfatide and 18F-FDG PET imaging in LLC tumor-bearing C57BL/6 mice model.

Yuchun Wei - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

Fludeoxyglucose (18F)

Icotinib and rh-endostatin as first line therapy in advanced non small cell line cancer patients harboring activating epidermal growth factor receptor mutations.

Qiong Zhao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Recombinant human endostatin

Pegylated arginase treatment in mesothelioma xenograft models.

James C. M. Ho - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mesothelioma

Arginine hydrochloride

Filters

24782 Abstracts